Alumis to merge with ACELYRIN in a $320m deal.

Alumis, a clinical-stage biopharmaceutical company, agreed to merge with ACELYRIN, a late-stage clinical biopharma company, in a $320m deal. “Through this combination with ACELYRIN, Alumis will have the financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab, and build commercial capabilities. Since completing our IPO, Alumis has operated with speed and rigor, and the multiple development milestones expected in 2025 and 2026, coupled with potential additional indications for ESK-001, represent exciting breakthroughs for our patients and value-driving opportunities for the combined company’s stockholders. As we move forward together, we will maintain financial discipline and a flexible capital allocation strategy with the goal of maximizing the value of our highly differentiated portfolio,” Martin Babler, Alumis President, CEO and Chairman.